A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
Sponsor: AMAG Pharmaceuticals, Inc.
A PHASE3 clinical study on Iron Deficiency Anemia, this trial is completed. The trial is conducted by AMAG Pharmaceuticals, Inc. and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AMAG Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Ballarat, Australia , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Brasov, Romania , Bucharest, Romania , Békéscsaba, Hungary , Cambridge, United Kingdom , Cape Town, South Africa and 58 more locations